Evidence map›Paper›PMID 32784558›Full record

ArticlePharmaceuticals (Basel, Switzerland)2020

Comparative In Vitro Toxicology of Novel Cytoprotective Short-Chain Naphthoquinones.

Zikai Feng, Mohammed Sedeeq, Abraham Daniel, Monika Corban, Krystel L Woolley, Ryan Condie, Iman Azimi, Jason A Smith, Nuri Gueven

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceuticals (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.8field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Zikai FengSchool of Pharmacy and Pharmacology, University of Tasmania, Hobart, TAS 7005, Australia.ORCID 0000-0001-8788-3659
Mohammed SedeeqSchool of Pharmacy and Pharmacology, University of Tasmania, Hobart, TAS 7005, Australia.
Abraham DanielSchool of Pharmacy and Pharmacology, University of Tasmania, Hobart, TAS 7005, Australia.ORCID 0000-0002-3650-7837
Monika CorbanSchool of Pharmacy and Pharmacology, University of Tasmania, Hobart, TAS 7005, Australia.
Krystel L WoolleySchool of Natural Sciences, University of Tasmania, Hobart, TAS 7005, Australia.
Ryan CondieSchool of Natural Sciences, University of Tasmania, Hobart, TAS 7005, Australia.
Iman AzimiSchool of Pharmacy and Pharmacology, University of Tasmania, Hobart, TAS 7005, Australia.ORCID 0000-0001-9477-9999
Jason A SmithSchool of Natural Sciences, University of Tasmania, Hobart, TAS 7005, Australia.
Nuri GuevenSchool of Pharmacy and Pharmacology, University of Tasmania, Hobart, TAS 7005, Australia.ORCID 0000-0003-3782-767X
University of Tasmania · AU

Funding

National Foundation for Medical Research and Innovation N/A
6 · The paper itself

Abstract

Short-chain quinones (SCQs) have been identified as potential drug candidates against mitochondrial dysfunction, which largely depends on the reversible redox characteristics of the active quinone core. We recently identified 11 naphthoquinone derivatives,

Indexed as

cytotoxicityidebenonemitochondriashort-chain quinone

Identifiers

PMID32784558
PMCPMC7463972
OpenAlexW3048193415

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.